...
机译:氘的安全性和功效氘化止吐剂治疗
Center for Neurological Restoration;
Former employee of Teva Pharmaceuticals;
Teva Pharmaceuticals Frazer;
Jean and Paul Amos Parkinson’s Disease and Movement Disorder Program Emory University School of;
University of South Florida Parkinson’s Disease and Movement Disorders Center;
Baylor College of Medicine;
Methodist Neurological Institute;
University of North Carolina at Chapel Hill School of Medicine;
Yale University School of Medicine;
Northwestern University Feinberg School of Medicine;
University of Tennessee Health Science Center;
University of Utah;
Georgetown University;
tardive dyskinesia; deutetrabenazine; movement disorders; vmat2 inhibitor;
机译:氘的安全性和功效氘化止吐剂治疗
机译:德丁苯苯齐毒品用于迟钝的障碍:对新批准的新型药物治疗的疗效和安全性剖面系统审查 - 如何治疗的数量,危害或伤害可能性所需的数量?
机译:34通过伴随的多巴胺受体拮抗剂和基线合并症的迟发性止吐肽的长期氘氘化治疗反应
机译:使用光子进行光动力疗法的近期和长期疗效以及安全性? (FOTOLON?)-七年临床经验
机译:使用Markov链蒙特卡罗方法对事件时间和纵向数据进行联合建模,并将其应用于Proscar(TM)的长期疗效和安全性研究。
机译:缬沙坦和氘苯特那嗪治疗迟发性运动障碍的系统评价
机译:158德替四巴嗪的长期安全性用于治疗Tardive Dyskinesia:开放标签的结果,长期研究